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A C C E P T E D M A N U S C R I P T

Introduction
Mucosal vaccination is the most effective route to induce a local protective immune response against infections originating at mucosal surfaces (Shalaby, 1995) . The oral route offers potential for convenient administration of vaccines that achieve mucosal immune response following specific targeting of antigens to the gut associated lymphoid tissue (GALT). The gastrointestinal tract, however, is an environment that presents several barriers to vaccinemediated production of mucosal immune response. The presence of these barriers necessitates the use of appropriate delivery systems to ensure antigen protection from degradation, enhanced uptake/absorption and immune cell activation.
Chitosan (CS), a polymer derived from chitin, has become one of the most researched polymers in drug delivery due to its promising utility as an absorption enhancer. The capacity of CS to facilitate drug delivery across mucosal surfaces is attributed to its mucoadhesive properties and its ability to open the epithelial tight junctions, as structures that keep adjacent epithelial cells in close proximity with one another. A number of studies by our group Vllasaliu et al., 2010; Vllasaliu, Fowler, & Stolnik, 2014) have convincingly confirmed CS's ability to promote macromolecular absorption in vitro across intestinal and airway epithelial models.
CS and its soluble derivate, N-trimethyl chitosan (TMC), in both solution or particulate forms, have demonstrated clear potential for improved oral delivery of peptide and protein drugs (Chen et al., 2008; Sandri et al., 2007; van der Merwe, Verhoef, Verheijden, Kotze, & Junginger, 2004; Vllasaliu et al., 2012) . CS has also been explored widely as a component of particulate delivery systems with the potential to enable clinically effective oral administration of vaccines (Guo, Li, Lin, & Zhang, 2016; Li et al., 2017; Vera Ramirez, Sharpe, & Peppas, 2017) . This is because antigen encapsulation in particles is considered to be a key strategy in overcoming the hurdles of poor antigen immunogenicity and degradation in the gastrointestinal tract (Soares, Jesus, & Borges, 2017) . However, it is not entirely clear presently whether the proven absorption enhancing property of CS is useful in promoting antigen uptake and a therapeutically relevant immune response following oral delivery of antigens.
M-cells in the follicle-associated epithelium (FAE) of intestinal Peyer's patches, which actively sample the gut lumen transporting antigens to the underlying mucosal lymphoid tissue for processing and initiation of an immune response, are an obvious target in oral vaccine delivery (Slutter et al., 2009) . It has been shown that nanoparticles are actively taken up by the FAE through M-cells (Beloqui, Brayden, Artursson, Preat, & des Rieux, 2017) . Therefore, it has been suggested that the use of a nanoparticulate delivery system may function as a double-edged sword, increasing the uptake into epithelium and subsequently the uptake into antigen presenting cells (APCs) (Slutter et al., 2009) . Whether an enhanced transepithelial permeation of macromolecules (e.g. antigens), which can be afforded by CS nanoparticles, is translated into an improved immune response in vivo is not clear.
This work set out to compare the in vitro and in vivo oral vaccine delivery effects of CS chloride (213 kDa average molecular weight) as a CS salt that has consistently shown absorption enhancing properties in vitro in our previous work Vllasaliu et al., 2012; Vllasaliu et al., 2010) . CS nanoparticles were formulated via a commonly employed ionic gelation method , incorporating ovalbumin (OVA) as a model antigen. Nanoparticles were then characterised for size, charge and ability to incorporate and release the model antigen cargo. The effect of CS:OVA nanoparticles on cell viability, epithelial tight junctions and transepithelial permeation of the antigen was tested in Caco-2 cell monolayers as an in vitro intestinal model. The system's ability to produce immune responses was subsequently tested in vivo.
Materials and Methods
Materials
Different types of ovalbumins were used: fluorescein isothiocyanate (FITC)-labelled ovalbumin (OVA) (FITC-OVA, 3 moles dye/mole), purchased from Thermo Fisher Scientific (USA); non-labelled OVA, purchased from Sigma-Aldrich (UK); and endotoxin-free OVA (EndoGrade ® ), purchased from Cambridge Bioscience (UK). Ultrapure CS chloride of 213
kDa average molecular weight ('Protasan UP CL 213') was obtained from Novamatrix (Norway). Tripolyphosphate (TPP), Triton X-100, 2-(N-morpholino)ethanesulfonic acid (MES), paraformaldehyde and Fluoroshield with DAPI were all purchased from Sigma-Aldrich (UK). Caco-2 cells were attained from the European Collection of Cell Cultures (ECACC) and used between passages 57-88. Hank's Balanced Salt Solution (HBSS) (with sodium bicarbonate, without phenol red), phosphate buffered saline (PBS) tablets and trypsin were purchased from Sigma-Aldrich (UK). Transwell permeable inserts of 12 mm diameter and 0.4 µm pore size were obtained from Costar (USA). 3-(4,5-dimethylthiazol-2-yl)-5(3-carboxymethonyphenol)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) reagent, which is commercially known as 'CellTiter 96 AQueous One Solution Cell Proliferation Assay', was obtained from Promega (USA). For the lactate dehydrogenase (LDH) assay, the 'Pierce LDH Cytotoxicity Assay Kit' (Thermo Scientific, USA) was used. Goat, anti-mouse IgG H & L (Horse Radish Peroxidase, HRP) pre-absorbed was purchased from Abcam (UK). Goat, antimouse IgA-HRP was obtained from Invitrogen (UK) and goat, anti-mouse IgG1-HRP was sourced from Southern Biotech (USA).
Nanoparticle formulation and characterisation CS:OVA nanoparticles were prepared at different ratios. First, stock solutions of 2 mg/ml CS and 2 mg/ml OVA were prepared in dH2O. As a chloride salt, the specific CS used in this work dissolved in dH2O with continuous stirring in approximately 20 minutes. Once dissolved, CS was mixed with OVA, creating a 1 mg/ml concentration (both CS and OVA, i.e. 1:1 mass ratio). TPP solution (1 mg/ml in dH2O) was then added dropwise using a syringe with continuous stirring. TPP was added slowly until the solution appeared opalescent, indicating the formation of nanoparticles. Unlabelled OVA was used for nanoparticle characterisation, TEER and cytotoxicity studies, while FITC-OVA was employed in system fabrication for permeability studies.
Nanoparticles were characterised for size and surface charge. Size was characterised by nanoparticle tracking analysis (NTA) using a Nanosight LM10 HS instrument (Malvern, UK). Following formulation, CS:OVA nanoparticles were diluted in dH2O or Hank's Buffered Salt Solution (HBSS), supplemented with 2-(N-morpholino)ethanesulfonic acid (MES) buffer at 10 mM to create a pH of 6.0. The latter was done to replicate the biological solution used in cell studies.
Zeta potential measurements were carried out for nanoparticles with and without OVA, both in dH2O and HBSS to compare the effect of OVA on CS nanoparticle surface charge, as well as the effect of the biological buffer (high ionic strength) on the system's surface charge. Zeta potential was measured using a Zetasizer Nano ZS instrument (Malvern, UK).
Antigen complexation and release form nanoparticles CS:OVA nanoparticles (1:1 mass ratio; 1 mg/ml) were prepared as described earlier, using FITC-OVA. Fluorescence of the resulting nanoparticle suspension was measured using a Tecan Infinite M200 Pro plate reader (Tecan Group ltd, Switzerland) using excitation and emission wavelengths of 488 nm and 520 nm, respectively. 1 ml of 1 mg/ml heparin in dH2O or dH2O (control) was applied to the CS:OVA nanoparticle suspension and the mixture was incubated for 30 minutes at room temperature. Thereafter, the mixture was processed for ultrafiltration using Vivaspin centrifugal concentrator tubes of 1,000 kDa molecular weight cutoff (MWCO), using centrifugation time and force specified by the manufacturer. Following centrifugation, the fluorescence of the filtrate was measured and compared to fluorescence values prior to filtration.
Cell culture
Caco-2 cells were routinely maintained in 75 cm 2 flasks at 37 °C, 5% CO2 and 95% relative humidity. Dulbeco's Modified Eagle's Medium (DMEM) was used as the culture medium; this was supplemented with antibiotic and antimycotic solution (10,000 units of penicillin, 10 mg streptomycin and 25 µg amphotericin) and 10% v/v foetal bovine serum (FBS, European origin). Culture medium was replaced every two to three days.
For use as polarised monolayers modelling the intestinal epithelium, Caco-2 cells were initially detached from flasks using trypsin and seeded on 12-well Transwell permeable
5 to 2x10 5 cells per 1.1 cm 2 insert. Cells were then cultured for 21 days, with regular replacement of culture medium (every two to three days).
Cell toxicity studies MTS assay. Caco-2 cells were seeded on a clear 96-well plate and incubated for 24 hours prior to the assay. Samples were applied at different concentrations in HBSS. A 10% v/v solution of Triton X-100 in HBSS was used as a positive control and HBSS as a negative control. Samples were applied for three hours, following which the assay was conducted according to manufacturer's instructions, with absorbance measurements at 490nm using a Tecan Infinite M200 Pro plate reader.
The relative cell metabolic activity (%) was calculated using the following equation:
Where: S is the absorbance of cells incubated with tested samples; T is the absorbance of cells incubated with Triton X-100; H is the absorbance of cells incubated with HBSS.
LDH assay. Caco-2 cells were seeded on a clear 96-well plate and cultured for 48 hours before the assay. Samples were applied dissolved in HBSS, with 10% v/v Triton X-100 in HBSS and HBSS alone used as a positive and negative controls, respectively. Samples were applied to the cells for three hours and the assay performed following the manufacturer's instructions, with absorbance measured at 490 nm by a Tecan Infinite M200 Pro plate reader.
LDH release was calculated as a percentage relative to the controls, using the following equation:
Where: S is absorbance of the tested samples; H is absorbance of HBSS; T is absorbance of Triton X-100.
Transepithelial electrical resistance studies
Transepithelial electrical resistance (TEER) studies were conducted to measure the tight junction-opening effect of CS:OVA. Caco-2 cell monolayers were cultured on Transwell inserts for 21 days. Culture medium was initially replaced with HBSS and the cells placed in an incubator for 40-45 minutes to allow adjustment to the change in environment. TEER was measured before sample application ('time zero'). CS:OVA samples were then applied to the apical side of cell monolayers at different concentrations, in HBSS. TEER was subsequently recorded every 30 minutes for three hours, followed by a final 'reversibility measurement', 24 hours post-sample application (samples were removed after three hours incubation and cells incubated with the culture medium until the final TEER measurement).
OVA permeability study
Caco-2 monolayers displaying a minimum TEER of 900 Ωcm 2 were considered suitable for the permeability studies. TEER measurements were taken before the permeability study to confirm the polarity and integrity of the cell monolayers. Culture medium was replaced with HBSS and cells incubated at 37°C/5% CO2 for 40-45 minutes to acclimatise to HBSS. Test samples, consisting of CS:OVA (FITC-OVA) nanoparticles were then applied on the apical side of cell monolayers. CS:OVA translocation across the cell monolayers was determined by sampling the basolateral solution (100 µl) at regular intervals (every 30 min for 3 hours), with replacement of the sampled solutions with HBSS. CS:OVA translocation was determined by quantifying FITC-OVA through fluorescence measurements (488 nm excitation and 520 nm emission).
Permeability is expressed as the apparent permeability coefficient (Papp), which was calculated using the following equation: Each sample/dilution was tested in duplicates and data are presented as mean end point titre for IgG (reciprocal of serum dilution giving optical density > mean blank+2 standard deviation) and as mean optical density for the IgA response.
Statistical Analysis
Statistical comparisons for nanoparticle characterisation, toxicity assays, TEER and permeability studies were performed using a Students t-test for two groups and ANOVA in multiple group comparisons. Statistical analysis for ELISA data was performed using the Mann Whitney U test. p values of <0.05 were considered statistically significant. Figure 1 reveals size and surface charge data for CS:OVA nanoparticles (1:1 mass ratio) in HBSS ( Figure 1A ) and in dH2O ( Figure 1B) . The data highlight a lower mean and mode of 138.1 and 126.1 nm, respectively, in HBSS compared to dH2O (411.3 and 196.5 nm, respectively) . The data also show that the nanoparticles sample is relatively monodisperse in HBSS, while in dH2O particulate species of multiple sizes are present.
Results
Nanoparticle characterisation
Figure 1. Size characterisation of CS:OVA nanoparticles in Hank's Balanced Salt Solution (HBSS) (A) and dH2O (B), using nanoparticle tracking analysis (NTA) with a Nanosight LM10 HS instrument. Table 1 compares the zeta potential (surface charge) of CS:OVA nanoparticles against CS nanoparticles (no OVA) in HBSS and dH2O. Nanoparticles displayed a lower surface charge in HBSS compared to dH2O, specifically +9.68 mv and +37.9 mv, respectively. The zeta potential of CS:OVA systems (+9.68 mv) is lower compared to CS only nanoparticles (+13.1). Complexation and release studies were carried out to determine the ability and efficiency of CS and OVA to complex into CS:OVA nanoparticles. Figure 2 shows the release of OVA from formulated CS:OVA nanoparticles (FITC-OVA was used to enable quantitation, but referred to 'OVA'). The fluorescence of 1:1 mass ratio of the systems was measured before and after FITC-OVA release, which was triggered by exposure to heparin, followed by membrane ultrafiltration (using membranes permeable to the released FITC-OVA, but not CS:OVA nanoparticles). The fluorescence intensity of CS:OVA nanoparticle filtrate not treated with heparin is dramatically lower, 499, compared to 6904 before filtration. This suggests that some, namely 6.9% OVA (calculated by converting fluorescence into amount) is lost following filtration of CS:OVA nanoparticles, most likely attributed to excess OVA unincorporated into nanoparticles. However, 93.1% of OVA remains incorporated in CS:OVA nanoparticles with 1:1 mass ratio and these did not permeate the filters due to the inability of nanoparticles to permeate membranes with 1000 kDa molecular weight cut off (MWCO). On the other hand, with samples exposed to heparin to induce OVA release and then filtered, the fluorescence intensity of the filtrate was remarkably higher compared to that of filtrate where heparin treatment was omitted. In fact, fluorescence intensity in this scenario was only slightly lower to that pre-filtration (6232.16 vs 7175), suggesting that 86.8% of OVA was released from CS:OVA nanocomplexes (and permeation through 1000 kDa MWCO ultrafiltration membranes) following exposure to heparin. Cell toxicity studies Figure 3A shows CS:OVA nanoparticle toxicity, as determined in Caco-2 cells via the MTS assay. The data show that the highest concentration of nanoparticles (0.1 mg/ml) resulted in a reduction of relative cell viability to approximately 62% (relative to negative control, HBSS, assumed to produce 100% viability and positive control, Triton X-100, assumed to induce total cell death and therefore 0% viability). As CS:OVA nanoparticle concentration decreased, the effect on relative cell viability diminished, although the difference between step increases in concentration was not statistically significant. CS:OVA nanoparticle concentration of 0.05 mg/ml displayed a reduction of relative cell viability to 85% and two lowest concentrations induced a small reduction of relative cell viability to 94-95%.
Membrane toxicity studies were also conducted for CS:OVA nanoparticles via the LDH assay. This assay measures the leakage of an intracellular enzyme, lactate dehydrogenase (LDH), which occurs upon plasma membrane damage. As a measure of cell membrane integrity, the LDH assay is important to study the toxicity of positively charged systems such as CS. The data in Figure 3B clearly show that CS:OVA nanoparticles were associated with low levels of LDH release (between 2-4%) in Caco-2 cells, with the difference in effect between concentrations not statistically significant.
A) B)
Figure 3. Toxicity of chitosan:ovalbumin (CS:OVA) nanoparticles. A) Effect of different concentrations of CS:OVA nanoparticles on Caco-2 relative viability, as determined by the MTS assay. Data shows the mean ± SD (n = 6). B) Effect of different concentrations of CS:OVA nanoparticles on lactate dehydrogenase (LDH) release. Hank's Balanced Salt Solution (HBSS) was used as a negative control and Triton X-100 as a positive control for cell death. Data shows the mean ± SD (n = 4). 
Transepithelial electrical resistance studies Figure 4 shows the effect of CS:OVA nanoparticles on Caco-2 cell monolayer TEER. Different concentrations of the systems were applied to the cells, as well as OVA itself as a control. OVA permeability study Apical-to-basolateral permeation of FITC-OVA following application of CS:OVA nanoparticles to Caco-2 monolayers is shown in Figure 5 . Note that only FITC-OVA was quantified in these studies (through fluorescence measurements) and it is not possible to state whether FITC-OVA crossed the cell monolayers complexed in CS:OVA nanoparticles or whether it was released en route. FITC-OVA permeability following application of CS:OVA nanoparticles was notably greater, specifically 4.5 times higher compared to FITC-OVA alone. 
In vivo studies
The ability of CS-encapsulated OVA to induce systemic (IgG) and mucosal (IgA) immune responses following oral immunisation was evaluated by immunising mice four times at weekly intervals with CS:OVA nanoparticles, OVA alone or with OVA-CTX as controls. Data 
This work used a specific CS molecule (ultrapure CS chloride salt, average molecular weight 213 kDa), which has previously consistently shown substantial absorption-enhancing effects by our group, to fabricate nanocomplexes with OVA as a model antigen. The aim of the study was to establish whether macromolecular absorption enhancement, as tested in the Caco-2 in vitro intestinal epithelial monolayer model, is translated into an induction of immune response in vivo.
CS:OVA nanoparticles fabricated in this work displayed diameters below 200 nm and a positive zeta potential at 1:1 mass ratio (Figure 1 and Table 1 , respectively). This is similar to previous work reporting CS:OVA nanosystems with size ranging from 83.66 nm (Wen, Xu, Zou, & Xu, 2011) to 350 nm (Amidi et al., 2006) . The lower surface charge (zeta potential) of CS:OVA nanoparticles compared to CS only systems is expected due to OVA's negative charge (reported zeta potential of -20 to -25 mV (Niu et al., 2014) at pH 6.0-6.7), attenuating CS's positive surface charge. The observed zeta potential values of CS:OVA nanoparticles of 37.9 mV and 9.68 mV in dH2O and HBSS, respectively, are comparable to other studies, which reported ranges between 7.88-25 mV (Jana, Maji, Nayak, Sen, & Basu, 2013; Schrøder, Long, & Olsen, 2014) .
Testing the ability of the carrier system to release the antigen payload is important as the incorporated antigen cargo must be available for immune-inducing effect. OVA release from CS:OVA nanoparticles was tested by the addition of a highly negatively charged molecule, heparin. This was based on competitive electrostatic interaction of heparin (which has a significantly higher negative charge than OVA) with the positively charged CS, releasing OVA from the nanocomplexes in the process. Following incubation with heparin and ultrafiltration, 86.8% of OVA (FITC-labelled) was released from the complexes in the filtrate, suggesting a high degree of antigen dissociation from nanocomplexes ( Figure 2 ).
The CS:OVA nanoparticles fabricated in this work did not display appreciable toxicity to Caco-2 cells, as confirmed by MTS and LDH assays. The MTS cell viability data ( Figure 3A) showed that the highest concentration of CS:OVA nanoparticles reduced Caco-2 viability between 15 and 38%, whereas the lower concentrations did not significantly reduce cell viability. The relative absence of cytotoxicity is also confirmed by the LDH assay, whereby CS:OVA nanoparticles at all tested concentrations did not significantly increase LDH release (below 5% in all cases). The relative absence of cytotoxicity with CS:OVA is likely to be helped by the presence of OVA in the system and the consequent reduction in the positive surface charge of nanoparticles, as demonstrated by zeta potential reduction. This is because charge dependency of nanoparticulate toxicity is a well demonstrated effect Naha, Davoren, Lyng, & Byrne, 2010; Schaeublin et al., 2011) .
TEER experiments were conducted to ascertain whether CS:OVA nanoparticles were capable of disrupting the intestinal epithelial barrier through tight junction opening as this biological effect has been demonstrated convincingly for CS by many groups. TEER reduction was observed following sample application, although the same observation was also apparent for OVA solution at concentration equivalent to that present in nanoparticles (0.1 mg/ml). As a result, it is not clear whether CS:OVA nanoparticles exert a tight junctionmodulating effect, although the pattern of TEER reduction was different with CS:OVA nanoparticles compared to OVA solution control. With all the concentrations of CS:OVA nanoparticle samples, the TEER decrease was reversible, which is another indication of nontoxicity.
CS nanoparticles have previously been shown to produce a clear effect on tight junctions, with a prior study by our group demonstrating a significant reduction of TEER (by more than 80%) in Caco-2 cell monolayers . It is possible that CS:OVA nanoparticles in this work did not offer a dramatic reduction in Caco-2 monolayer TEER due to surface charge reduction of the systems (from OVA presence). Such observation was reported by Sadeghi et al. (Sadeghi et al., 2008) , showing that nanoparticles consisting of CS and its quaternary ammonium derivatives loaded with insulin were less effective in facilitating paracellular transport across Caco-2 cell monolayers compared to the corresponding free
polymers and arguing that the reduced charge density at nanoparticle surface, compared to the soluble form of CS, was responsible for this finding.
Permeability studies were performed to determine whether OVA, as a model antigen complexed with CS into nanoparticles, permeated across the intestinal epithelium (represented by the Caco-2 model). Data demonstrate that OVA permeability is 5-fold higher following application of CS:OVA compared to the equivalent concentration of OVA solution. It must be noted that due to the nature of the experimental procedure, whereby fluorescentlylabelled OVA was quantified, it is not possible to establish whether CS:OVA nanoparticles permeated the cell monolayers or if OVA dissociated from the nanoparticles, before or during the transit process. The increase in OVA permeability across Caco-2 monolayers is notable considering the lack of clear effect on epithelial tight junctions. The mechanism responsible for this is therefore more likely to relate to nanoparticle uptake by, and translocation across, Caco-2 cells rather than paracellular transit. The relatively small size of CS:OVA nanoparticles prepared in this work is likely to facilitate the cell uptake of nanoparticles.
Following the demonstration of CS complexation with (and release of) OVA, a good overall toxicity profile and enhancement of OVA permeation across Caco-2 monolayers, the performance of the systems as mechanisms to promote oral vaccine delivery was evaluated in vivo. This is important as the in vitro outcome of many drug formulation systems is often not reproduced in vivo. In case of systems designed to deliver the therapeutic payload across the mucosal surfaces, current in vitro epithelial models may not faithfully represent the more complex mucosal surfaces, which consist of multiple cell types and have additional components that may act as important barriers to particulate delivery, with mucus and the basement membrane being obvious examples.
Induction of mucosal immune response following oral immunisation necessitates the use of a potent adjuvant to overcome induction of tolerance (Shalaby, W. S.1995) . The immunising antigens need to reach the gut associated lymphoid tissues GALT (e.g. Peyer's patches) to be able to induce a mucosal antibody response and the draining lymph nodes and, subsequently, the primary lymphoid organs for induction of systemic immune response. It is clear from our results that oral immunisation with CS-encapsulated OVA induced a substantial mucosal IgA response, which was similar to the response induced by OVA in the presence of the potent adjuvant, CTX. Interestingly, CS:OVA failed to induce a systemic IgG response, while the co-administration of OVA and CTX was able to induce a substantial IgG response in 3 out of 5 mice. This could be attributed to the large size of the CS:OVA particles (mean 138 nm), which may be able to reach the local mucosal lymphoid tissues, but probably failed to reach the draining lymph nodes and the central lymphoid organs subsequently, which is necessary for the induction of systemic immune response. It is also possible that the immunisation regimen used does not favour induction of systemic IgG as only 3/5 animals had a good level of IgG response after OVA+CTX immunisation and further studies are needed to address this point. Interestingly, we have recently shown in our lab that induction of a substantial systemic IgG response to orally delivered antigens requires five consecutive immunisations, even in the presence of a potent adjuvant, such as CTX.
Several studies reported successful induction of systemic and mucosal antibody response following oral immunisation with CS-encapsulated antigens. For example, a study by Biswas et al. (Biswas, Chattopadhyay, Sen, & Saha, 2015) used BALB/b mice in oral immunisation studies using alginate-coated CS nanoparticles encapsulating measles antigen, prepared via ionotropic gelation using tripolyphosphate. The study found the presence of measles specific IgG and IgA in the serum and an increase in IgA secretion from the intestinal lavages for low molecular weight alginate-coated CS nanoparticles. Another study utilising dual tetanus and diphtheria toxoid-loaded, stable CS-glucomannan nanoassemblies demonstrated humoral, mucosal and cellular immune response by eliciting complete protective levels of anti-tetanus toxoid and anti-diphtheria toxoids antibodies (Harde, Siddhapura, Agrawal, & Jain, 2015) . However, direct comparisons between this work and literature reports are not possible considering the many variables, such as different CS-based systems, incorporated antigens and immunisation regimens. With regards to the use of in vitro models for prediction of oral vaccine delivery, the importance of reliably modelling FAE is appreciated. FAE contains both enterocytes and specialised M cells, which are key in the process of luminal sampling and transport of antigens to lymphoid tissue cells beneath, initiating the mucosal immune response (Kiyono & Fukuyama, 2004) . In vitro, human M cell-like co-culture models are increasingly being used to investigate the uptake of nanoparticle-delivered antigens (des Rieux et al., 2007; Gullberg et al., 2000; Kerneis, Bogdanova, Kraehenbuhl, & Pringault, 1997; Kesisoglou, Schmiedlin-Ren, Fleisher, & Zimmermann, 2010) . Although these models are labour-intensive and there is high inter-laboratory variability, partly because of different approaches used to establish filtergrown Caco-2/Raji B cell co-culture systems (Ahmad, Gogarty, Walsh, & Brayden, 2017) , the use of these constructs is more appropriate in studies aiming to develop delivery systems for oral vaccine delivery. However, even in those situations one must exercise caution as these models do not represent the combination of physicochemical barriers present in the native mucosal tissue.
It is nevertheless interesting that a notably enhanced antigen permeability across the Caco-2 enterocyte system with CS:OVA nanoparticles was translated into an in vivo mucosal but not systemic immune response. This is particularly the case considering that compared with the Caco-2 monoculture used in the present study, M cell-like co-culture models are associated with increased particle translocation (Ahmad et al., 2017; Lai & D'Souza, 2008 ). An important conclusion from this study is that clear antigen absorption enhancement seen in vitro in the Caco-2 intestinal epithelial model, which has often been employed to study the potential of oral vaccine delivery systems, translates in mucosal but not systemic immune response following oral delivery in vivo.
Conclusion
This work confirmed the CS's ability to complex a model antigen into nano-size entities. Although these systems show interesting effects in vitro, namely notable augmentation of antigen delivery across an intestinal epithelial monolayer model, this does not reliably predict in vivo systemic immune response following oral delivery. 
